Sleep Problems in Children With ADHD Not Linked to Methylphenidate: Presented at AACAP
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Sleep Problems in Children With ADHD Not Linked to Methylphenidate: Presented at AACAP

By Maria Bishop

BOSTON, MA -- November 1, 2007 -- No significant effect of methylphenidate transdermal or oral formulation was observed on sleep problems in children taking the drug for attention-deficit hyperactivity disorder (ADHD), according to research presented here at the 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP).

Lead author Stephen V. Faraone, PhD, Director, Child and Adolescent Psychiatry Research, State University of New York Upstate Medical University, Syracuse, New York, United States stated that sleep problems are listed as common adverse effects of methylphenidate, but they have not been uniformly observed in clinical trials.

In his study, following screening and a washout phase, 282 children aged 6 to 12 diagnosed with ADHD were randomised to methylphenidate transdermal (n = 100), methylphenidate oral (n = 94) or placebo (n = 88). At baseline and every week throughout the study, parents/caregivers assessed sleep behaviour in the children on the Children's Sleep Habits Questionnaire (CSHQ), a 33-item questionnaire.

Subjects in the methylphenidate transdermal group received 10-mg, 15-mg, 20-mg and 30-mg patches; subjects in the oral group received doses of 18, 27, 36 and 53 mg. Titration upward was permitted after the subject had used the previous dose for at least 1 week. Tapering to a lower dose was permitted once.

After 5 weeks, among the methylphenidate transdermal, methylphenidate oral or placebo groups, there was no significant difference in the severity of sleep problems: CSHQ mean total scores were 45.7, 45.9 and 46.7, respectively.

Dr. Faraone noted that, with both methylphenidate formulations, baseline sleep scores predicted endpoint scores (P <.001).

This study was not powered to compare the two formulations of methylphenidate. Funding was provided by Shire Development Inc.

[Presentation title: Analysis of Sleep Effects in Children Treated With Once-Daily Methylphenidate: Abstract B30]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities